Overview

Bosentan in Children With Pulmonary Arterial Hypertension Extension Study

Status:
Completed
Trial end date:
2011-10-28
Target enrollment:
Participant gender:
Summary
The main objective of the FUTURE 2 study was to assess the long-term safety and tolerability of the pediatric formulation of bosentan in children with idiopathic pulmonary arterial hypertension or familial pulmonary arterial hypertension who completed FUTURE 1 study.
Phase:
Phase 3
Details
Lead Sponsor:
Actelion
Treatments:
Bosentan